期刊
JOURNAL OF NEURO-ONCOLOGY
卷 103, 期 2, 页码 371-379出版社
SPRINGER
DOI: 10.1007/s11060-010-0403-6
关键词
Glioblastoma; Angiogenesis; Bevacizumab; Vascular endothelial growth factor; Metronomic chemotherapy
资金
- NIH [5P50-NS-20023, 5 R37 CA11898, MO1 RR 30]
- NCRR
- NCI [1 P20 CA096890]
- Genentech Pharmaceuticals
We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial. Twenty-three patients received bevacizumab (10 mg/kg) every 2 weeks with either oral etoposide (50 mg/m(2)) daily for 21 consecutive days each month or daily temozolomide (50 mg/m(2)). The primary endpoint was 6-month progression-free survival (PFS-6) and secondary endpoints included safety and overall survival. Both the etoposide and temozolomide arms of the study closed at the interim analysis due to lack of adequate anti-tumor activity. No radiographic responses were observed. Although 12 patients (52%) achieved stable disease, PFS-6 was 4.4% and the median PFS was 7.3 weeks. The only grade 4 adverse event was reversible neutropenia. Grade 3 toxicities included fatigue (n = 2) and infection (n = 1). Metronomic etoposide or temozolomide is ineffective when administered with bevacizumab among recurrent GBM patients who have progressed on prior bevacizumab therapy. Alternative treatment strategies remain critically needed for this indication.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据